Sitagliptin fenilalanil hydrochloride

• CAT Number: I041312
• CAS Number: 1339954-75-4
• Molecular Formula: C25H25ClF6N6O2
• Molecular Weight: 590.95
• Purity: ≥95%
• Synonyms: (2S)-2-amino-N-[(2R)-4-oxo-4-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-1-(2,4,5-trifluorophenyl)butan-2-yl]-3-phenylpropanamide;hydrochloride
• InChI: InChI=1S/C25H24F6N6O2.ClH/c26-17-12-19(28)18(27)10-15(17)9-16(33-23(39)20(32)8-14-4-2-1-3-5-14)11-22(38)36-6-7-37-21(13-36)34-35-24(37)25(29,30)31;/h1-5,10,12,16,20H,6-9,11,13,32H2,(H,33,39);1H/t16-,20+;/m1./s1
• InChIKey: LZDQVWZJBLFZSN-PXPMWPIZSA-N
• SMILES: C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)NC(=O)[C@H](CC4=CC=CC=C4)N.Cl

Sitagliptin phenylalanine hydrochloride（Cat No.:I041312）is a combination compound involving sitagliptin, a widely used medication for type 2 diabetes, and phenylalanine, an amino acid derivative. Sitagliptin works by inhibiting the enzyme DPP-4 (dipeptidyl peptidase-4), which increases insulin production and decreases glucagon release, improving blood sugar control. The phenylalanine component may serve to improve drug stability or bioavailability. This combination aims to enhance the efficacy of sitagliptin, offering potential benefits in managing diabetes. Preclinical and clinical evaluations are focused on optimizing its therapeutic effects and reducing side effects compared to standard treatments.